Generate QR code
Open Access
Subscription Access
Preventive heparin therapy in obstetric practice
https://doi.org/10.30629/0023-2149-2024-102-9-10-727-735
Abstract
In obstetric practice, a significant number of patients receive anticoagulant medications for prophylactic purposes. This review presents the types of heparins used and examines clinical situations where prophylactic treatment with heparins is administered, including assisted reproductive technologies, obstetric complications of pregnancy, aspects of delivery, thrombotic complications, and extragenital pathology. The possibilities for improving the outcomes of prophylactic treatment with heparins and preventing arising complications are discussed.
About the Authors
A. P. Melnikov
Moscow Regional Research Institute of Obstetrics and Gynecology named after V.I. Krasnopolsky; Russian Association on Thrombosis, Hemostasis and Vascular Pathology named after A. Schmidt–B. Kudryashov
Russian Federation
Russian Federation
Andrey P. Melnikov — Candidate of Medical Sciences, Senior Researcher
Moscow
T. Yu. Khrustaleva
Moscow Regional Research Institute of Obstetrics and Gynecology named after V.I. Krasnopolsky
Russian Federation
Russian Federation
Taisiua Yu. Khrustaleva — clinical resident
Moscow
I. N. Bokarev
Russian Association on Thrombosis, Hemostasis and Vascular Pathology named after A. Schmidt–B. Kudryashov
Russian Federation
Russian Federation
Igor N. Bokarev — Doctor of Medical Sciences, Professor, President
Moscow
References
1. Dictionary of Foreign Words. Edition 8 stereotype. Pp. 416. “Russian language”. Moscow, 1981 (In Russian)].
2. Pastori D., Cormaci V.M., Marucci S., Franchino G., Del Sole F., Capozza A.et al. A Comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int. J. Mol. Sci. 2023;24(4):31–69. DOI: 10.3390/ijms24043169
3. Bates S.M., Rajasekhar A., Middeldorp S., McLintock C., Rodger M.A., James A.H.et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317–3359. DOI: 10.1182/bloodadvances.2018024802
4. Eke A.C. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. J. Basic Clin. Physiol. Pharmacol. 2022;33(5):581–598. DOI: 10.1515/jbcpp-2021-0312
5. Pariente G., Leibson T., Carls A., Adams-Webber T., Ito S., Koren G. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med. 2016;13(11): e1002160. eCollection 2016 Nov. DOI: 10.1371/journal.pmed.1002160
6. Abildgaard A., Madsen S.A., Hvas A.-M. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin. Thromb. Hemost. 2020;46(8):932–969. DOI: 10.1055/s-0040-1718405
7. Sultan A.A., West J., Tata L.J, Fleming K.M, Nelson-Piercy C., Grainge M. J. Risk of fi rst venous thromboembolism in and around pregnancy: a population-based cohort study. Br. J. Haematol. 2012;156(3):366–73. DOI: 10.1111/j.1365-2141.2011.08956.x
8. Sucker C. Prophylaxis and therapy of venous thrombotic events (VTE) in pregnancy and the postpartum period. Geburtshilfe Frauenheilkd. 2020. PMID: 31949319
9. Bauersachs R.M., Dudenhausen J., Faridi A., Fischer T., Fung S., Geisen U.et al. Risk stratifi cation and heparin prophylaxis to prevent venous thromboembolism in pregnant women. J. Thromb. Haemost. 2007;98(6):1237–45. DOI: 10.1160/th07-05-0329
10. Nicholson M.J., Chan N., Bhagirath V., Ginsberg J. Prevention of venous thromboembolism in 2020 and beyond. J. Clin. Med. 2020;9(8):2467. DOI: 10.3390/jcm9082467
11. Shabanova N.A., Zainulina M.S. Modern approaches to the prevention of thromboembolic complications in pregnancy. Journal of Obstetrics and Women’s Diseases, 2011;LX(3):161–168. (In Russian)].
12. Zakai N A, McClure L A. Racial diff erences in venous thromboembolism. J. Thromb. Haemost. 2011;9(10):1877–82. DOI: 10.1111/j.1538-7836.2011.04443.x
13. Nakayama T., Mitsuno R., Torimitsu T., Yoshimoto N., Kanda T., Tokuyama H.et al. Diffi culty in managing nephrotic syndrome-associated cerebral venous thrombosis. CEN Case Rep. 2021;10(1):132–138. DOI: 10.1007/s13730-020-00520-7
14. Melnikov A.P., Kashchuk M.G., Akhvlediani K.N., Bokarev I.N. Thrombophilia in obstetric practice. Clinicheskya Medicina 2021;99(1):15–20. (In Russian)].
15. Arachchillage D.J., Mackillop L., Chandratheva A., Motawani J., MacCallum P., Laff an M. Thrombophilia testing: A British Society for Haematology guideline. Br. J. Haematol. 2022;198(3):443–458. DOI: 10.1111/bjh.18239
16. Folkeringa N., Brouwer J.L.P., Korteweg F. J., Veeger N.J.G.M., Erwich J.J.H.M., Holm J. P., van der Meer J. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S defi cient women. Clinical Trial Br. J. Haematol. 2007;136(4):656–61. DOI: 10.1111/j.1365-2141.2006.06480.x
17. Mukhopadhyay S., Johnson T.A., Duru N., Buzza M.S., Pawar N.R., Sarkar R., Antalis T.M. Fibrinolysis and infl ammation in venous thrombus resolution. Front. Immunol. 2019;10:1348. DOI: 10.3389/fimmu.2019.01348
18. Huang Y., Li F., Li C., Liao X. Effi cacy of low molecular weight heparin in preventing perinatal venous thrombosis: a meta-analysis. Comput. Math. Methods Med. 2022;2022:1248577. DOI: 10.1155/2022/1248577
19. Wiegers H.M.G., Middeldorp S. Contemporary best practice in the management of pulmonary embolism during pregnancy. Ther. Adv. Respir. Dis. 2020;14:1753466620914222. DOI: 10.1177/1753466620914222
20. Wiegers H.M. G., Farkas D. K., Horváth-Puhó E., Middeldorp S., van Es N., Sørensen H. T. Incidence and prognosis of superfi cial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study. The Lancet Haematology. 2023;10(5):e359– e366. DOI: 10.1016/S2352-3026(23)00013-3.
21. Notten P., van Laanen J.H.H., Eijgenraam P., de Wolf M.A.F., Kurstjens R.L.M., ten Cate H., ten Cate‐Hoek A. Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting. J. Res. Pract. Thromb. Haemost. 2020;4(4):594–603. DOI: 10.1002/rth2.12330
22. Bistervels I.M., Geerlings A. E., Bonta P. ., Ganzevoort W., Zijlstra I.J.A.J., Middeldorp S. Pregnancy in women with an inferior vena cava fi lter: a tertiary center experience and overview of the literature. Blood Adv. 2021;5(20):4044–4053. DOI: 10.1182/bloodadvances.2020003930
23. Manasanch E.E., Lozier G.N. Venous thromboembolism. pp.338–355 in The Bethesda Handbook of Clinical Hematology. (4 ed.) Editors: G.P. Rodgers, N.S. Young. Wolters Kluver. 2018.
24. Bianca I., Geraci G., Gulizia M.M., Assenza G.E., Barone C., Campisi M.et al. Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases. Eur. Heart J. Suppl. 2017;19(D):D256–D292. DOI: 10.1093/eurheartj/sux032
25. Shu L., Bakradze E., Omran S.S., Giles J., Amar J., Henninger N.et al. Predictors of recurrent venous thrombosis after cerebral venous thrombosis. Neurology. 2022;99(21):e2368–e2377. DOI: 10.1212/WNL.0000000000201122
26. Roeder H.J., Lopez J. R., Miller E.C. Ischemic stroke and cerebral venous sinus thrombosis in pregnancy. Handb. Clin. Neurol. 2020;172:3–31.DOI: 10.1016/B978-0-444-64240-0.00001-5
27. Sharma N., Sharma S.R., Hussain M. An audit of cerebral venous thrombosis associated with pregnancy and puerperium in teaching hospital in North Eastern India. J. Family Med. Prim. Care. 2019;8(3):1054–1057.DOI: 10.4103/jfmpc.jfmpc_366_18
28. Meng S.-H., Li J-H., Zuo L-J., Feng L.-M. The outcomes of pregnant and postpartum patients with cerebral venous sinus thrombosis after anticoagulant therapy. Monitoring editor: Baradwan S.M. Medicine (Baltimore). 2021;100(26):e26360. DOI: 10.1097/MD.0000000000026360
29. Hamulyák E.N., Scheres L. J.J, Marijnen M.C., Goddijn M., Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst. Rev. 2020;2020(5):CD012852. DOI: 10.1002/14651858.CD012852.pub2
30. Bala M.M., Paszek E., Lesniak W., Wloch-Kopec D., Jasinska K., Undas A. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst. Rev. 2018;7(7):CD012534. DOI: 10.1002/14651858.CD012534.pub2
31. Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.-M., Vandvik P. O. VTE, thrombophilia, antithrombotic therapy, and pregnancy . Chest. 2012;141(2):e691S–e736S. DOI: 10.1378/chest.11-2300
32. Chaturvedi S., Braunstein E. M., Brodsky R.A. Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications. J. Thromb. Haemost. 2021;19(3):607–616. DOI: 10.1111/jth.15082
33. Antic D., Lefkou E., Otasevic V., Banfi c L., Dimakakos E., Oli nic D. et al. Position paper on the management of pregnancy-associated superfi cial venous thrombosis. Clin. Appl. Thromb. Hemost. 2022;28:1076029620939181. DOI: 10.1177/1076029620939181
34. Malhamé I., Othman M., Casais P., D’Souza R., Wald R. M., Silversides C. K., Sermer M., Shehata N.Communication from the ISTH SSC Subcommittee on Women’s Health Issues in Thrombosis and Haemostasis: A Survey on Anticoagulation for Mechanical Heart Valves in Pregnancy. J. Thromb. Haemost. 2021;19:859–864. DOI: 10.1111/jth.15213.
35. Kariv S., Azibani F., Baard J., Sliwa K., Osman A., Anthony J., Soma-Pillay P. Cardiovasc J. Haemorrhage and other complications in pregnant women on anticoagulation for mechanical heart valves: a prospective observational cohort study. Afr. 2018;29(5):289–295. DOI: 1 0.5830/CVJA-2018-029
36. Origa R., Comitini F. Mediterr J. Pregnancy in thalassemia. Hematol. Infect. Dis. 2019,11(1):e2019019, DOI: 10.4084/MJHID.2019.019
37. Geddings J. E., Mackman N. Recently identifi ed factors that regulate hemostasis and thrombosis. Thromb. Haemost. 2014;111(4):570–574. DOI:10.1160/TH13-10-0812
38. Chiodelli P., Bugatti A., Urbinati C., Rusnati M. Heparin/heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules. 2015;20(4):6342–88. DOI: 10.3390/molecules20046342
39. Nikolaeva M.G., Grigorieva E.E., Serdyuk G.V. Mamot A.P.The role of genetic determinants of thrombophilias in the realization of women’s reproductive function. Materials of the X Anniversary All-Russian Scientifi c Forum “Mother and Child” 29.09.2009–02.10.2009, Moscow. pp. 144–145. (In Russian)].
40. Agarkova T.A., Trifonova E.A., Gabitova N.A. et al. Analysis of genetic markers of hereditary thrombophilia and endothelial dysfunction in complicated pregnancy. pp. 6–7. Materials of the XI Anniversary All-Russian Scientifi c Forum “Mother and Child” 28.09.2009–01.10.2010, Moscow. (In Russian)].
41. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn S R, Magee L A, Rodger M. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Randomized Controlled Trial J. Thromb. Haemost. 2009;7(1):58–64. DOI: 10.1111/j.1538-7836.2008.03230.x
42. Huang J., Chen X., Xing H., Chen L., Xie Z., He S.et al. Aspirin and heparin for the prevention of pre-eclampsia: protocol for a systematic review and network meta-analysis. BMJ Open. 2019;9(2):e026920. DOI: 10.1136/bmjopen-2018-026920
43. Ed. J. Hirsh. Venous thromboembolism, trombophilia and pregnancy, pp 133-139 in Guidelines for Antithrombotic Therapy. 8th edition, 2008.
44. Dias A.T.B., Modesto T.B., de Oliveira S.A. Eff ectiveness of the use of Low Molecular Heparin in patients with repetition abortion history: Systematic review and meta-analysis. JBRA Assist. Reprod. 2021;25(1):10–27.DOI: 10.5935/1518-0557.20200042
45. Skeith L. Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation. Hematology Am. Soc. Hematol. Educ. Program. 2021; 2021(1):559–569. DOI: 10.1182/hematology.2021000291
46. Timp J. F., Braekkan S. K., Lijfering W. M., van Hylckama Vlieg A., Rosendaal F. R., le Cessie S., Cannegieter S.C., Rahimi K. Prediction of recurrent venous thrombosis in all patients with a fi rst venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). PLoS Med. 2019;16(10):e1002883. DOI: 10.1371/journal.pmed.1002883
47. Sahoo D.R., Dorairajan G., Palanivel C. Risk stratifi cation for venous thrombosis in post-partum women in a tertiary care setup in south India. Indian J. Med. Res. 2020;152(5):523–526. DOI: 10.4103/ijmr.IJMR_1564_18
48. Posch F., Thaler J., Zlabinger G-J., Königsbrügge O., Koder S., Zielinski C., Pabinger I., Ay C. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Clin. Cancer Res. 2016;22(1):200-6. DOI: 10.1158/1078-0432.CCR-14-3358
49. Chaturvedi S., Braunstein E.M., Yuan X., Yu J., Alexander A., Chen H. et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239–25. 1DOI: 10.1182/blood.2019003863
50. Memtsas V.P., Arachchillage D.R. J., Gorog D.A., Muszbek L. Role, laboratory assessment and clinical relevance of fi brin, factor XIII and endogenous fi brinolysis in arterial and venous thrombosis. Int. J. Mol. Sci. 2021;22(3):1472. DOI: 10.3390/ijms22031472
Review
For citations:
Melnikov A.P., Khrustaleva T.Yu., Bokarev I.N. Preventive heparin therapy in obstetric practice. Clinical Medicine (Russian Journal). 2024;102(9-10):727–735. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-9-10-727-735
Views:
172
Email this article 